You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

Medical Care

Global Oral Anti-diabetes Drugs Market Research Report 2021, Competitive Analysis, Industry Growth Trends And Forecast 2027

Diabetes is a chronic disease that occurs when the body cannot effectively use the produced insulin or the pancreas does not produce sufficient insulin. The pancreas is an organ that sits behind the stomach and releases hormones into the digestive system. Diabetes is categorized by increased levels of blood glucose, which can cause severe damage to blood vessels, heart, kidneys, nerves, and eyes. Diabetes is also called hyperglycemia or raised blood sugar. Insulin is a hormone that regulates the blood sugar level in body. Continuous increase in blood sugar leads to diabetes. Uncontrollable diabetes can damage the nervous system and other body systems. Diabetes is of two types: type 1 and type 2. Type 1 diabetes, also known as juvenile diabetes or insulin-dependent diabetes, arises when the immune system misguidedly attacks and kills the beta cells of the pancreas. In type 1 diabetes, little or no insulin is released into the body, owing to this sugar builds up in the blood instead of being used as energy. Type 1 diabetes is rare, and only 10% of people with diabetes have type 1 diabetes. It commonly occurs in childhood or adolescence. Type 2 diabetes arises when the body cannot appropriately use the insulin that is released or does not make enough insulin. As a consequence, sugar builds up in the blood instead of being used as energy. About 90% of people with diabetes have type 2 diabetes.
Market Analysis and Insights: Global Oral Anti-diabetes Drugs Market
The global Oral Anti-diabetes Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Oral Anti-diabetes Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Oral Anti-diabetes Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Oral Anti-diabetes Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Oral Anti-diabetes Drugs market.
Oral Anti-diabetes Drugs Breakdown Data by Type
by Type
Liquid
Capsule
Tablet
by Drug Class
Sulfonylureas
Meglitinides
Biguanides
Others
Oral Anti-diabetes Drugs Breakdown Data by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Based on regional and country-level analysis, the Oral Anti-diabetes Drugs market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Oral Anti-diabetes Drugs market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2016-2021. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2016-2021.
The following players are covered in this report:
Sanofi
Eli Lilly
AstraZeneca plc
Astellas Pharma Inc
Johnson & Johnson (Janssen Pharmaceuticals)
Boehringer Ingelheim
Merck
Takeda
Bristol Myers Squibb
Novartis
Pfizer
Abbott
Biocon
Sunpharma
Novo Nordisk
Piramal Healthcare
Bayer Healthcare
Dr. Reddy’s Laboratories Ltd
Glenmark Pharmaceuticals Ltd
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oral Anti-diabetes Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Liquid
1.2.3 Capsule
1.2.4 Tablet
1.3 Market by Application
1.3.1 Global Oral Anti-diabetes Drugs Market Share by Distribution Channel: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Oral Anti-diabetes Drugs Market Perspective (2016-2027)
2.2 Oral Anti-diabetes Drugs Growth Trends by Regions
2.2.1 Oral Anti-diabetes Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Oral Anti-diabetes Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Oral Anti-diabetes Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Oral Anti-diabetes Drugs Industry Dynamic
2.3.1 Oral Anti-diabetes Drugs Market Trends
2.3.2 Oral Anti-diabetes Drugs Market Drivers
2.3.3 Oral Anti-diabetes Drugs Market Challenges
2.3.4 Oral Anti-diabetes Drugs Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Oral Anti-diabetes Drugs Players by Revenue
3.1.1 Global Top Oral Anti-diabetes Drugs Players by Revenue (2016-2021)
3.1.2 Global Oral Anti-diabetes Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Oral Anti-diabetes Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Oral Anti-diabetes Drugs Revenue
3.4 Global Oral Anti-diabetes Drugs Market Concentration Ratio
3.4.1 Global Oral Anti-diabetes Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oral Anti-diabetes Drugs Revenue in 2020
3.5 Oral Anti-diabetes Drugs Key Players Head office and Area Served
3.6 Key Players Oral Anti-diabetes Drugs Product Solution and Service
3.7 Date of Enter into Oral Anti-diabetes Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Oral Anti-diabetes Drugs Breakdown Data by Type
4.1 Global Oral Anti-diabetes Drugs Historic Market Size by Type (2016-2021)
4.2 Global Oral Anti-diabetes Drugs Forecasted Market Size by Type (2022-2027)

5 Oral Anti-diabetes Drugs Breakdown Data by Distribution Channel
5.1 Global Oral Anti-diabetes Drugs Historic Market Size by Distribution Channel (2016-2021)
5.2 Global Oral Anti-diabetes Drugs Forecasted Market Size by Distribution Channel (2022-2027)

6 North America
6.1 North America Oral Anti-diabetes Drugs Market Size (2016-2027)
6.2 North America Oral Anti-diabetes Drugs Market Size by Type
6.2.1 North America Oral Anti-diabetes Drugs Market Size by Type (2016-2021)
6.2.2 North America Oral Anti-diabetes Drugs Market Size by Type (2022-2027)
6.2.3 North America Oral Anti-diabetes Drugs Market Size by Type (2016-2027)
6.3 North America Oral Anti-diabetes Drugs Market Size by Distribution Channel
6.3.1 North America Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2021)
6.3.2 North America Oral Anti-diabetes Drugs Market Size by Distribution Channel (2022-2027)
6.3.3 North America Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2027)
6.4 North America Oral Anti-diabetes Drugs Market Size by Country
6.4.1 North America Oral Anti-diabetes Drugs Market Size by Country (2016-2021)
6.4.2 North America Oral Anti-diabetes Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Oral Anti-diabetes Drugs Market Size (2016-2027)
7.2 Europe Oral Anti-diabetes Drugs Market Size by Type
7.2.1 Europe Oral Anti-diabetes Drugs Market Size by Type (2016-2021)
7.2.2 Europe Oral Anti-diabetes Drugs Market Size by Type (2022-2027)
7.2.3 Europe Oral Anti-diabetes Drugs Market Size by Type (2016-2027)
7.3 Europe Oral Anti-diabetes Drugs Market Size by Distribution Channel
7.3.1 Europe Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2021)
7.3.2 Europe Oral Anti-diabetes Drugs Market Size by Distribution Channel (2022-2027)
7.3.3 Europe Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2027)
7.4 Europe Oral Anti-diabetes Drugs Market Size by Country
7.4.1 Europe Oral Anti-diabetes Drugs Market Size by Country (2016-2021)
7.4.2 Europe Oral Anti-diabetes Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Oral Anti-diabetes Drugs Market Size (2016-2027)
8.2 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Type
8.2.1 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Distribution Channel
8.3.1 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2021)
8.3.2 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Distribution Channel (2022-2027)
8.3.3 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2027)
8.4 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Region
8.4.1 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Oral Anti-diabetes Drugs Market Size (2016-2027)
9.2 Latin America Oral Anti-diabetes Drugs Market Size by Type
9.2.1 Latin America Oral Anti-diabetes Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Oral Anti-diabetes Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Oral Anti-diabetes Drugs Market Size by Type (2016-2027)
9.3 Latin America Oral Anti-diabetes Drugs Market Size by Distribution Channel
9.3.1 Latin America Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2021)
9.3.2 Latin America Oral Anti-diabetes Drugs Market Size by Distribution Channel (2022-2027)
9.3.3 Latin America Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2027)
9.4 Latin America Oral Anti-diabetes Drugs Market Size by Country
9.4.1 Latin America Oral Anti-diabetes Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Oral Anti-diabetes Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Oral Anti-diabetes Drugs Market Size (2016-2027)
10.2 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Type
10.2.1 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Distribution Channel
10.3.1 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2021)
10.3.2 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Distribution Channel (2022-2027)
10.3.3 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2027)
10.4 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Country
10.4.1 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Oral Anti-diabetes Drugs Introduction
11.1.4 Sanofi Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.1.5 Sanofi Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Details
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Oral Anti-diabetes Drugs Introduction
11.2.4 Eli Lilly Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.2.5 Eli Lilly Recent Development
11.3 AstraZeneca plc
11.3.1 AstraZeneca plc Company Details
11.3.2 AstraZeneca plc Business Overview
11.3.3 AstraZeneca plc Oral Anti-diabetes Drugs Introduction
11.3.4 AstraZeneca plc Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.3.5 AstraZeneca plc Recent Development
11.4 Astellas Pharma Inc
11.4.1 Astellas Pharma Inc Company Details
11.4.2 Astellas Pharma Inc Business Overview
11.4.3 Astellas Pharma Inc Oral Anti-diabetes Drugs Introduction
11.4.4 Astellas Pharma Inc Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.4.5 Astellas Pharma Inc Recent Development
11.5 Johnson & Johnson (Janssen Pharmaceuticals)
11.5.1 Johnson & Johnson (Janssen Pharmaceuticals) Company Details
11.5.2 Johnson & Johnson (Janssen Pharmaceuticals) Business Overview
11.5.3 Johnson & Johnson (Janssen Pharmaceuticals) Oral Anti-diabetes Drugs Introduction
11.5.4 Johnson & Johnson (Janssen Pharmaceuticals) Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.5.5 Johnson & Johnson (Janssen Pharmaceuticals) Recent Development
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Company Details
11.6.2 Boehringer Ingelheim Business Overview
11.6.3 Boehringer Ingelheim Oral Anti-diabetes Drugs Introduction
11.6.4 Boehringer Ingelheim Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.6.5 Boehringer Ingelheim Recent Development
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Oral Anti-diabetes Drugs Introduction
11.7.4 Merck Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.7.5 Merck Recent Development
11.8 Takeda
11.8.1 Takeda Company Details
11.8.2 Takeda Business Overview
11.8.3 Takeda Oral Anti-diabetes Drugs Introduction
11.8.4 Takeda Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.8.5 Takeda Recent Development
11.9 Bristol Myers Squibb
11.9.1 Bristol Myers Squibb Company Details
11.9.2 Bristol Myers Squibb Business Overview
11.9.3 Bristol Myers Squibb Oral Anti-diabetes Drugs Introduction
11.9.4 Bristol Myers Squibb Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.9.5 Bristol Myers Squibb Recent Development
11.10 Novartis
11.10.1 Novartis Company Details
11.10.2 Novartis Business Overview
11.10.3 Novartis Oral Anti-diabetes Drugs Introduction
11.10.4 Novartis Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.10.5 Novartis Recent Development
11.11 Pfizer
11.11.1 Pfizer Company Details
11.11.2 Pfizer Business Overview
11.11.3 Pfizer Oral Anti-diabetes Drugs Introduction
11.11.4 Pfizer Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.11.5 Pfizer Recent Development
11.12 Abbott
11.12.1 Abbott Company Details
11.12.2 Abbott Business Overview
11.12.3 Abbott Oral Anti-diabetes Drugs Introduction
11.12.4 Abbott Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.12.5 Abbott Recent Development
11.13 Biocon
11.13.1 Biocon Company Details
11.13.2 Biocon Business Overview
11.13.3 Biocon Oral Anti-diabetes Drugs Introduction
11.13.4 Biocon Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.13.5 Biocon Recent Development
11.14 Sunpharma
11.14.1 Sunpharma Company Details
11.14.2 Sunpharma Business Overview
11.14.3 Sunpharma Oral Anti-diabetes Drugs Introduction
11.14.4 Sunpharma Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.14.5 Sunpharma Recent Development
11.15 Novo Nordisk
11.15.1 Novo Nordisk Company Details
11.15.2 Novo Nordisk Business Overview
11.15.3 Novo Nordisk Oral Anti-diabetes Drugs Introduction
11.15.4 Novo Nordisk Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.15.5 Novo Nordisk Recent Development
11.16 Piramal Healthcare
11.16.1 Piramal Healthcare Company Details
11.16.2 Piramal Healthcare Business Overview
11.16.3 Piramal Healthcare Oral Anti-diabetes Drugs Introduction
11.16.4 Piramal Healthcare Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.16.5 Piramal Healthcare Recent Development
11.17 Bayer Healthcare
11.17.1 Bayer Healthcare Company Details
11.17.2 Bayer Healthcare Business Overview
11.17.3 Bayer Healthcare Oral Anti-diabetes Drugs Introduction
11.17.4 Bayer Healthcare Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.17.5 Bayer Healthcare Recent Development
11.18 Dr. Reddy’s Laboratories Ltd
11.18.1 Dr. Reddy’s Laboratories Ltd Company Details
11.18.2 Dr. Reddy’s Laboratories Ltd Business Overview
11.18.3 Dr. Reddy’s Laboratories Ltd Oral Anti-diabetes Drugs Introduction
11.18.4 Dr. Reddy’s Laboratories Ltd Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.18.5 Dr. Reddy’s Laboratories Ltd Recent Development
11.18 Glenmark Pharmaceuticals Ltd
.1 Glenmark Pharmaceuticals Ltd Company Details
.2 Glenmark Pharmaceuticals Ltd Business Overview
.3 Glenmark Pharmaceuticals Ltd Oral Anti-diabetes Drugs Introduction
.4 Glenmark Pharmaceuticals Ltd Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
.5 Glenmark Pharmaceuticals Ltd Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
  • FORMAT: PDF
  • PUBLISHED DATE: Apr, 2021
  • NO OF PAGES: 102